missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ SV2A Monoclonal Antibody (K70011_14F1), Invitrogen™
Description
Sequence of this protein is as follows: FIRGAKDIAK EVKKHAAKKV VKGLDRVQDE YSRRSYSRFE EEDDDDDFPA PSDGYYRGEG TQDEEEGGAS SDATEGHDED DEIYEGEYQG IPRAESGGKG ERMADGAPLA GVRGGLSDGE GPPGGRGEAQ RRKEREELAQ QYEAILRECG
This protein plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission. Positively regulates vesicle fusion by maintaining the readily releasable pool of secretory vesicles.It is identified as the brain binding-site for the antiepileptic drug levetiracetam/lev.
Specifications
Specifications
| Antigen | SV2A |
| Applications | Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blot |
| Classification | Monoclonal |
| Clone | K70011_14F1 |
| Concentration | 0.71 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 50% glycerol, 0.5% BSA and 0.09% sodium azide |
| Gene | SV2A |
| Gene Accession No. | Q02563, Q7L0J3 |
| Gene Alias | AI746429; calcium regulator SV2A; Kiaa0736; mKIAA0736; PSEC0174; SV2; SV2A; synaptic vesicle glycoprotein 2 a; synaptic vesicle glycoprotein 2a; Synaptic vesicle protein 2; synaptic vesicle protein 2A; synaptic vesicle transmembrane transporter (SV2) RNA |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?